• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comirnaty（BNT162b2，辉瑞/生物科技）疫苗在意大利威尼托特雷维索省预防医护人员感染 SARS-CoV-2 的效果，2020 年 12 月 27 日至 2021 年 3 月 24 日。

Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.

机构信息

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Local Health Unit (ULSS 2 Marca Trevigiana), Treviso, Italy.

出版信息

Euro Surveill. 2021 Apr;26(17). doi: 10.2807/1560-7917.ES.2021.26.17.2100420.

DOI:10.2807/1560-7917.ES.2021.26.17.2100420
PMID:33928898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8086247/
Abstract

Data on effectiveness of the BioNTech-/Pfizer COVID-19 vaccine in real-world settings are limited. In a study of 6,423 healthcare workers in Treviso Province, Italy, we estimated that, within the time intervals of 14-21 days from the first and at least 7 days from the second dose, vaccine effectiveness in preventing SARS-CoV-2 infection was 84% (95% confidence interval (CI): 40-96) and 95% (95% CI: 62-99), respectively. These results could support the ongoing vaccination campaigns by providing evidence for targeted communication.

摘要

有关真实环境中 BioNTech-/辉瑞 COVID-19 疫苗有效性的数据有限。在一项针对意大利特雷维索省 6423 名医护人员的研究中，我们估计，在第一剂后 14-21 天和第二剂后至少 7 天的时间间隔内，疫苗预防 SARS-CoV-2 感染的有效性分别为 84%（95%置信区间[CI]：40-96）和 95%（95%CI：62-99）。这些结果可以为有针对性的沟通提供证据，从而支持正在进行的疫苗接种活动。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c52a/8086247/181c711106f1/2100420-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c52a/8086247/658157d625b9/2100420-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c52a/8086247/181c711106f1/2100420-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c52a/8086247/658157d625b9/2100420-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c52a/8086247/181c711106f1/2100420-f2.jpg

相似文献

1
Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.Comirnaty（BNT162b2，辉瑞/生物科技）疫苗在意大利威尼托特雷维索省预防医护人员感染 SARS-CoV-2 的效果，2020 年 12 月 27 日至 2021 年 3 月 24 日。
Euro Surveill. 2021 Apr;26(17). doi: 10.2807/1560-7917.ES.2021.26.17.2100420.
2
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
3
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.BNT162b2 疫苗和 mRNA-1273 新冠疫苗在预防医护人员、第一响应者和其他必要及一线工作人员感染 SARS-CoV-2 中的疫苗有效性的临时估计-2020 年 12 月至 2021 年 3 月美国 8 个地点。
MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3.
4
Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.BNT162b2 疫苗接种与医护人员中出现有症状和无症状 SARS-CoV-2 感染的相关性。
JAMA. 2021 Jun 22;325(24):2457-2465. doi: 10.1001/jama.2021.7152.
5
[Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].[卡斯蒂利亚-莱昂社会医疗中心工作人员接种辉瑞/生物科技公司的BNT162b2 mRNA疫苗后对严重急性呼吸综合征冠状病毒2的体液免疫。]
Rev Esp Salud Publica. 2021 Oct 25;95:e202110141.
6
Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.根据既往感染状况，定量检测辉瑞-生物科技和牛津-阿斯利康疫苗对 SARS-CoV-2 刺突蛋白的抗体反应。
Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14. doi: 10.1016/j.cmi.2021.05.041. Epub 2021 Jun 7.
7
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.新冠病毒疫苗接种和既往感染后对 SARS-CoV-2 的保护作用。
N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16.
8
Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.日本医护人员中乙型肝炎病毒疫苗反应史与对辉瑞/BioNTech 的 BNT162b2 mRNA 新冠疫苗刺突抗体反应的相关性：一项前瞻性观察性研究。
PLoS One. 2022 May 16;17(5):e0268529. doi: 10.1371/journal.pone.0268529. eCollection 2022.
9
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
10
Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study.COVID-19 BNT162b2 疫苗（辉瑞-生物科技，Comirnaty）接种后医护人员不良事件的主动监测：一项横断面研究。
J Community Health. 2022 Apr;47(2):211-225. doi: 10.1007/s10900-021-01039-3. Epub 2021 Oct 9.

引用本文的文献

1
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy.细胞外囊泡在心血管稳态与疾病中的作用：在诊断和治疗中的潜在作用
Nat Rev Cardiol. 2025 Mar 5. doi: 10.1038/s41569-025-01141-2.
2
Healthcare workers safety: a cohort study using healthcare utilisation databases on vaccination and vaccine timeliness impact against SARS-CoV-2 infection.医护人员安全：一项队列研究，利用医疗保健利用数据库评估疫苗接种及疫苗及时性对严重急性呼吸综合征冠状病毒2感染的影响
Sci Rep. 2025 Jan 2;15(1):162. doi: 10.1038/s41598-024-84100-0.
3
COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.

本文引用的文献

1
Impact of tiered restrictions on human activities and the epidemiology of the second wave of COVID-19 in Italy.分层限制对人类活动的影响和意大利第二波 COVID-19 流行病学。
Nat Commun. 2021 Jul 27;12(1):4570. doi: 10.1038/s41467-021-24832-z.
2
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.英格兰医护人员的 COVID-19 疫苗接种率和 BNT162b2 mRNA 疫苗对感染的有效性（SIREN）：一项前瞻性、多中心、队列研究。
Lancet. 2021 May 8;397(10286):1725-1735. doi: 10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23.
3
新冠病毒疫苗对医护人员预防有症状感染和严重感染有效：一项临床综述。
Vaccine X. 2024 Aug 5;20:100546. doi: 10.1016/j.jvacx.2024.100546. eCollection 2024 Oct.
4
The Dynamic Risk of COVID-19-Related Events in Vaccinated Healthcare Workers (HCWs) from a Tertiary Hospital in Bucharest, Romania: A Study Based on Active Surveillance Data.罗马尼亚布加勒斯特一家三级医院接种疫苗的医护人员中与 COVID-19 相关事件的动态风险：一项基于主动监测数据的研究
Vaccines (Basel). 2024 Feb 11;12(2):182. doi: 10.3390/vaccines12020182.
5
Characterization of SARS-CoV-2 Variants in Military and Civilian Personnel of an Air Force Airport during Three Pandemic Waves in Italy.意大利三次疫情浪潮期间空军机场军事和文职人员中新型冠状病毒变异株的特征分析
Microorganisms. 2023 Nov 5;11(11):2711. doi: 10.3390/microorganisms11112711.
6
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines.SARS-CoV-2 的发病机制概述及 COVID-19 疫苗的最新进展。
Biomolecules. 2023 Oct 24;13(11):1565. doi: 10.3390/biom13111565.
7
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review.辉瑞/生物技术、莫德纳和阿斯利康疫苗对 SARS-CoV-2 的疫苗效力：系统评价。
Front Public Health. 2023 Oct 24;11:1229716. doi: 10.3389/fpubh.2023.1229716. eCollection 2023.
8
Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges.基于小干扰 RNA（siRNA）的抗病毒治疗应用：原理、潜力和挑战。
J Biomed Sci. 2023 Oct 16;30(1):88. doi: 10.1186/s12929-023-00981-9.
9
Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics.脂质纳米颗粒的免疫原性及其对 mRNA 疫苗和治疗药物疗效的影响。
Exp Mol Med. 2023 Oct;55(10):2085-2096. doi: 10.1038/s12276-023-01086-x. Epub 2023 Oct 2.
10
COVID-19 vaccine effectiveness among healthcare workers: a hospital-based cohort study.COVID-19 疫苗在医护人员中的有效性：一项基于医院的队列研究。
BMJ Open. 2023 May 2;13(5):e068996. doi: 10.1136/bmjopen-2022-068996.
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
BNT162b2疫苗接种者中SARS-CoV-2感染和新冠肺炎的早期感染率降低情况。
Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy.全国封锁对 SARS-CoV-2 传染性的影响，意大利。
Emerg Infect Dis. 2021 Jan;27(1):267-70. doi: 10.3201/eid2701.202114. Epub 2020 Oct 20.
6
Graphing survival curve estimates for time-dependent covariates.绘制随时间变化协变量的生存曲线估计值。
Int J Methods Psychiatr Res. 2002;11(2):68-74. doi: 10.1002/mpr.124.